Pluristem Therapeutics Inc Applies For U.S. Approval Of Bone Marrow Drug- Reuters

Reuters reported that Pluristem Therapeutics Inc will apply to the U.S. Food and Drug Administration for approval of its placenta-based stem cell treatment for aplastic bone marrow as an orphan drug or rare disease treatment, it said on July 23, 2012. Gaining orphan drug status is part of Pluristem's strategy for penetrating the bone marrow recovery market, starting with treatment of aplastic anaemia, a disease that affects five to 10 people in every million. In 2011, Pluristem received orphan drug status for its cell therapy in the treatment of Buerger's disease, a rare blood vessel disease.